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The growth in the medicines bill for innovative drugs in the United Kingdom is the lowest in Europe.' Funding new treatments within the NHS is difficult: drug budgets are overspent by significant amounts and mechanisms for obtaining new money for medical advances are simply not working.2 Unless there is a more planned approach to spending on drugs -which takes into account the introduction of new treatments -then the time lag before patients can benefit will continue to be unnecessarily long.
The introduction of new treatments is not simply a matter of funding. Other issues include evidence for the effectiveness of the new treatments, the relative benefits of a new treatment against established treatments, and understanding the wider effects of the introduction of a new treatment. Taking a narrow view of the costs of treatment may mask potential cost benefits of a new treatment. The difficulties of introducing a new treatment are well illustrated by the problems experienced in securing the funding and the appropriate service structure for surfactant treatment of preterm babies with respiratory distress syndrome. 
